-
Saudi Arabia and other countries adhere to the position of reducing production, crude oil rebounds by more than 1%
Time of Update: 2023-01-05
Saudi Arabia firmly took the position of OPEC+ production cuts, and the United Arab Emirates also denied rumors of production increases, and international oil prices closed higher on Tuesday.
-
Express psoriasis symptoms are significantly alleviated! Phase 1 trials of oral IL-17 inhibitors have yielded positive results
Time of Update: 2022-10-20
▎WuXi AppTec content team editor A few days ago, DICE Therapeutics announced that its oral inhibitor DC-806, which targets IL-17, has achieved positive results in a phase 1 clinical trial 。 These resu
-
Weight loss of up to 10 kg in 6 weeks, Pfizer two oral GLP-1 receptor agonists clinical results are positive
Time of Update: 2022-10-01
▲PF-07081532 dose-dependent type reduces patient weight (Source: Pfizer official website)The trial results released today also include the results of a 16-week phase 2b clinical trial of danuglipron in the treatment of patients with type 2 diabetes.
-
Express 75% of patients maintained complete remission after one year, with positive Phase 2
Time of Update: 2022-06-17
▎WuXi AppTec Content Team Editor Today, CG Oncology announced that the company's oncolytic virus therapy CG0070, in combination with Merck's anti-PD-1 antibody Keytruda, has been approved in a Phase 2 clinical trial for the treatment of non-muscle invasive bladder cancer.
-
Yifang Bio's new KRAS G12C inhibitor achieved positive results in Phase 1 clinical trials
Time of Update: 2022-05-23
Transfer from | Medicine GuanlanRecently, Yifang Bio announced the first clinical data of its oral KRAS G12C inhibitor in cancer patients .
This time, Yifang Bio presented its Phase 1 clinical data of its oral KRAS G12C inhibitor at the AACR .
-
siRNA therapy can reduce important risk factors of cardiovascular disease by 98%. Phase 1 clinical results of siRNA therapy are positive
Time of Update: 2022-05-02
Silence Therapeutics announced today that its investigational small interfering RNA (siRNA) therapy SLN360 has achieved positive results in a single-dose escalation Phase 1 clinical trial .
References:[1] Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a).
-
patients with advanced PD-L1 positive (CPS≧1) gastric/gastroesophageal junction (GEJ) cancer (KEYNOTE-063)
Time of Update: 2022-04-24
The study showed that the KEYNOTE-063 study results were consistent with the global KEYNOTE-061 study results, and pembrolizumab did not improve the efficacy of Asian PD-L1-positive gastric/gastroesophageal junction (GEJ) cancer patients compared with second-line paclitaxel .
-
J INTERN MED: Symptoms and functional impairment at 1 year in SARS-CoV-2 positive and negative individuals
Time of Update: 2022-04-19
5% of SARS-CoV-2-positive individuals reported impaired function at 12 months compared with 6.
1-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals .
134821-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals leave a comment here
-
for breast cancer patients with ER-positive low expression (IHC 1%-10%)
Time of Update: 2022-04-15
Recently, the journal Cancer published the results of a retrospective propensity-matched analysis from Fudan University Cancer Hospital , mainly evaluating the use of short-course (2-3 years) adjuvant in patients with ER-positive low-expression (IHC 1%-10%) breast cancer.
-
The world's first first-line treatment of SCLC with positive results of PD-1 inhibitor data announced!
Time of Update: 2021-12-29
The ASTRUM-005 study is a randomized, double-blind, international multi-center, phase III clinical study that evaluated slulimumab and placebo combined with chemotherapy for the treatment of previously untreated extensive-stage small cell lung cancer (ES-SCLC) Patient effectiveness and safety .
-
Twist Bioscience is now selling a synthetic RNA positive control for the new crown mutant strain
Time of Update: 2021-12-24
South San Francisco, California, USA--(Business Wire)--December 15, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers obtain A successful company, the company today announced the launch of a synthetic RNA positive control for the SARS-CoV-2 mutant strain Omi Keron (B.
-
Express delivery of 100% of patients achieved complete remission, and the Phase 2 clinical results of the oncolytic virus/PD-1 antibody combination are positive
Time of Update: 2021-12-07
▎The content team editor of WuXi AppTec recently, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, combined with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer , These patients did not respond to BCG treatment .
-
100% of patients achieve complete remission of oncolytic virus/PD-1 antibody combination Phase 2 clinical results are positive
Time of Update: 2021-12-02
A few days ago, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, in combination with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer.
-
Using custom AAV capsids to improve drug delivery ophthalmic gene therapy Phase 1 trial results are positive
Time of Update: 2021-11-05
On October 10, 2021, 4D Molecular Therapeutics (4DMT) announced that its intravitreal injection of gene therapy 4D-125 has achieved a positive mid-term in a phase 1/2 clinical trial for patients with advanced X-linked retinitis pigmentosa (XLRP) Safety and clinical activity data .
-
vTv Therapeutics' breakthrough type 1 diabetes therapy mechanism research achieves positive results
Time of Update: 2021-10-21
On October 12, vTv Therapeutics announced that the study of the mechanism of TTP399 in the treatment of type 1 diabetes has obtained positive results, proving that patients with type 1 diabetes who received TTP399 did not have an increase in keto acid levels during the withdrawal of insulin treatment compared with the placebo group, which means that TTP399 does not Increase the risk of ketoacidosis .